NASDAQ · Biotechnology

Structure Therapeutics Inc. (GPCR) Stock

$53.36 -3.23% NASDAQ: GPCR Healthcare

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R).

Valuation

MetricValue
Price$53.36
Market Cap$3.07B
P/E Ratio-20.21
P/B Ratio2.67
P/S Ratio0.00
EPS (TTM)$-2.40
52-Week High$94.90
52-Week Low$15.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-15.14%
ROA-11.31%
ROCE-14.46%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio26.16

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-38.0M$-53.0M$-103.0M$-158.0M$-288.0M
Net Profit$-40.0M$-51.0M$-90.0M$-123.0M$-141.0M
EPS$-1.20$-1.44$-2.43$-2.34$-2.40
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$111.0M$98.0M$482.0M$903.0M$1.6B
Total Liabilities$176.0M$213.0M$29.0M$38.0M$68.0M
Cash$105.0M$26.0M$130.0M$170.0M$800.0M
Borrowings$1.0M$0$5.0M$4.0M$6.0M

Latest News

Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now Insider Monkey · Jul 3, 2026 After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching 24/7 Wall St. · Jun 24, 2026 H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR) Insider Monkey · Jun 17, 2026 Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron Insider Monkey · Jun 8, 2026 Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)? Simply Wall St. · Jun 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$-46.0M$-79.0M$-117.0M$-222.0M
Investing Cash Flow$17.0M$-62.0M$-271.0M$-360.0M$86.0M
Financing Cash Flow$0$-2.0M$-21.0M$1.0M$-5.0M
Net Cash Flow$89.0M$-79.0M$104.0M$40.0M$630.0M
Free Cash Flow$-33.0M$-46.0M$-82.0M$-118.0M$-226.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.00
EV / EBITDA-16.46
FCF Yield-5.18%
Quick Ratio26.16
Interest Coverage0.00
Return 1Y176.86%
Return 3Y47.77%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABCL $6.93 +6.13% -5.91 $2.12B 0.00%
CLDX $35.80 +0.63% -7.84 $2.38B 0.00%
EWTX $43.52 -2.03% -14.63 $4.68B 0.00%
GLPGGalapagos N.V. $27.98 +1.71% 3.57 $1.84B 0.00%
LQDA $84.15 -0.33% 332.94 $7.48B 0.00%

About Structure Therapeutics Inc.

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

Structure Therapeutics Inc. is headquartered in US.

Structure Therapeutics Inc. (GPCR) stock trades at $53.36 with a market capitalization of $3.07B. The stock is valued at a price-to-earnings (P/E) ratio of -20.21, price-to-book of 2.67, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $15.80 and $94.90, and currently trades 43.8% below its 52-week high.

On profitability, Structure Therapeutics Inc. generates a return on equity (ROE) of -15.14%, return on capital employed of -14.46%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: structuretx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides